156 related articles for article (PubMed ID: 31544510)
1. Treatment patterns and overall survival among patients with unresectable, stage III non-small-cell lung cancer.
Bobbili P; Ryan K; Duh MS; Dua A; Fernandes AW; Pavilack M; Gomez JE
Future Oncol; 2019 Oct; 15(29):3381-3393. PubMed ID: 31544510
[No Abstract] [Full Text] [Related]
2. Long-term survival trends in patients with unresectable stage III non-small cell lung cancer receiving chemotherapy and radiation therapy: a SEER cancer registry analysis.
Hansen RN; Zhang Y; Seal B; Ryan K; Yong C; Darilay A; Ramsey SD
BMC Cancer; 2020 Apr; 20(1):276. PubMed ID: 32248816
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Factor and Clinical Outcome in Stage III Non-Small Cell Lung Cancer: A Study Based on Real-World Clinical Data in the Korean Population.
Kim HC; Ji W; Lee JC; Kim HR; Song SY; Choi CM; ;
Cancer Res Treat; 2021 Oct; 53(4):1033-1041. PubMed ID: 33592139
[TBL] [Abstract][Full Text] [Related]
4. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
[TBL] [Abstract][Full Text] [Related]
5. Consolidation treatment of durvalumab after chemoradiation in real-world patients with stage III unresectable non-small cell lung cancer.
Chu CH; Chiu TH; Wang CC; Chang WC; Huang AC; Liu CY; Wang CL; Ko HW; Chung FT; Hsu PC; Guo YK; Kuo CS; Yang CT
Thorac Cancer; 2020 Jun; 11(6):1541-1549. PubMed ID: 32281272
[TBL] [Abstract][Full Text] [Related]
6. Optimizing Survival of Patients With Marginally Operable Stage IIIA Non-Small-Cell Lung Cancer Receiving Chemoradiotherapy With or Without Surgery.
Yang KL; Chang YC; Ko HL; Chi MS; Wang HE; Hsu PS; Lin CC; Yeh DY; Kao SJ; Jiang JS; Chi KH
Clin Lung Cancer; 2016 Nov; 17(6):550-557. PubMed ID: 27378175
[TBL] [Abstract][Full Text] [Related]
7. Current status and progress of concurrent chemoradiotherapy in patients with locally advanced non-small cell lung cancer prior to the approval of durvalumab.
Fukui T; Hosotani S; Soda I; Ozawa T; Kusuhara S; Kakegawa MI; Kasajima M; Hiyoshi Y; Igawa S; Yokoba M; Mitsufuji H; Kubota M; Katagiri M; Sasaki J; Ishiyama H; Naoki K
Thorac Cancer; 2020 Apr; 11(4):1005-1014. PubMed ID: 32057187
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of Elderly Patients Who Receive Combined Modality Therapy for Locally Advanced Non-Small-Cell Lung Cancer.
Zaki M; Dominello M; Dyson G; Gadgeel S; Wozniak A; Miller S; Paximadis P
Clin Lung Cancer; 2017 Jan; 18(1):e21-e26. PubMed ID: 27567356
[TBL] [Abstract][Full Text] [Related]
9. Different administration routes of recombinant human endostatin combined with concurrent chemoradiotherapy might lead to different efficacy and safety profile in unresectable stage III non-small cell lung cancer: Updated follow-up results from two phase II trials.
Honglian M; Zhouguang H; Fang P; Lujun Z; Dongming L; Yujin X; Yong B; Liming X; Yirui Z; Xiao H; Jin W; Yue K; Lvhua W; Ming C
Thorac Cancer; 2020 Apr; 11(4):898-906. PubMed ID: 32068962
[TBL] [Abstract][Full Text] [Related]
10. Comparison of seventh TNM and eighth TNM staging system in stage III non-small cell lung cancer patients treated with concurrent chemoradiotherapy.
Yılmaz U; Özdemir Ö; Yılmaz Ü
Curr Probl Cancer; 2019 Feb; 43(1):33-42. PubMed ID: 29804944
[No Abstract] [Full Text] [Related]
11. Population-based patterns of treatment and survival for patients with stage I and II non-small cell lung cancer aged 65-74 years and 75 years or older.
Driessen E; Detillon D; Bootsma G; De Ruysscher D; Veen E; Aarts M; Janssen-Heijnen M
J Geriatr Oncol; 2019 Jul; 10(4):547-554. PubMed ID: 30876833
[TBL] [Abstract][Full Text] [Related]
12. Impact of histology on patterns of failure and clinical outcomes in patients treated with definitive chemoradiotherapy for locally advanced non-small cell lung cancer.
Ito H; Matsuo Y; Ohtsu S; Nishimura T; Terada Y; Sakamoto T; Mizowaki T
Int J Clin Oncol; 2020 Feb; 25(2):274-281. PubMed ID: 31667664
[TBL] [Abstract][Full Text] [Related]
13. Survival nomogram for patients with initially diagnosed metastatic non-small-cell lung cancer: a SEER-based study.
Wang Y; Pang Z; Chen X; Bie F; Wang Y; Wang G; Liu Q; Du J
Future Oncol; 2019 Oct; 15(29):3395-3409. PubMed ID: 31512954
[No Abstract] [Full Text] [Related]
14. Prognostic significance of weight gain during definitive chemoradiotherapy for locally advanced non-small-cell lung cancer.
Sher DJ; Gielda BT; Liptay MJ; Warren WH; Batus M; Fidler MJ; Garg S; Bonomi P
Clin Lung Cancer; 2013 Jul; 14(4):370-5. PubMed ID: 23260389
[TBL] [Abstract][Full Text] [Related]
15. Cisplatin vs. carboplatin-based chemoradiotherapy in patients >65 years of age with stage III non-small cell lung cancer.
Ezer N; Smith CB; Galsky MD; Mhango G; Gu F; Gomez J; Strauss GM; Wisnivesky J
Radiother Oncol; 2014 Aug; 112(2):272-8. PubMed ID: 25150635
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of pretreatment Glasgow prognostic score in stage IIIB geriatric non-small cell lung cancer patients undergoing radical chemoradiotherapy.
Topkan E; Bolukbasi Y; Ozdemir Y; Besen AA; Mertsoylu H; Selek U
J Geriatr Oncol; 2019 Jul; 10(4):567-572. PubMed ID: 31178158
[TBL] [Abstract][Full Text] [Related]
17. Stage III non-small-cell lung cancer: population-based patterns of treatment in British Columbia, Canada.
Vinod SK; Wai E; Alexander C; Tyldesley S; Murray N
J Thorac Oncol; 2012 Jul; 7(7):1155-63. PubMed ID: 22617240
[TBL] [Abstract][Full Text] [Related]
18. Patterns of locoregional failure in stage III non-small cell lung cancer treated with definitive chemoradiation therapy.
Garg S; Gielda BT; Kiel K; Turian JV; Fidler MJ; Batus M; Bonomi P; Sher DJ
Pract Radiat Oncol; 2014; 4(5):342-348. PubMed ID: 25194104
[TBL] [Abstract][Full Text] [Related]
19. Heart Dose Is an Independent Dosimetric Predictor of Overall Survival in Locally Advanced Non-Small Cell Lung Cancer.
Speirs CK; DeWees TA; Rehman S; Molotievschi A; Velez MA; Mullen D; Fergus S; Trovo M; Bradley JD; Robinson CG
J Thorac Oncol; 2017 Feb; 12(2):293-301. PubMed ID: 27743888
[TBL] [Abstract][Full Text] [Related]
20. Factors Associated With Survival in Complete Pathologic Response Non-Small Cell Lung Cancer.
Martinez-Meehan D; Lutfi W; Dhupar R; Christie N; Baker N; Schuchert M; Luketich JD; Okusanya OT
Clin Lung Cancer; 2020 Jul; 21(4):349-356. PubMed ID: 32299769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
